LNTH vs MYGN
Lantheus Holdings, Inc. and Myriad Genetics Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | LNTH | MYGN |
|---|---|---|
| Revenue | $1.5B | $824.5M |
| Net income | $233.6M | $-365.9M |
| Gross margin | 61.1% | 69.9% |
| Net margin | 15.2% | −44.4% |
| Return on equity | 21.4% | −68.5% |
| Diluted EPS | $3.41 | −$3.95 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | · |
| Equity | $1.1B | $368.0M |
| Net debt / equity | 0.19× | −0.08× |
| Current ratio | 2.70× | 2.49× |
| Revenue CAGR 5y | 35.3% | 8.2% |
| Profit CAGR 5y | · | · |
LNTH bills 1.9× the revenue of MYGN, and MYGN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | LNTH | MYGN |
|---|---|---|
| FY2025 | $1.5B | $824.5M |
| FY2024 | $1.5B | $837.6M |
| FY2023 | $1.3B | $753.2M |
| FY2022 | $935.1M | $678.4M |
| FY2021 | $425.2M | $690.6M |
| FY2020 | $339.4M | $557.1M |
| FY2019 | $347.3M | $638.6M |
| FY2018 | $343.4M | $851.1M |
| FY2017 | $331.4M | $743.7M |
| FY2016 | $301.9M | $728.7M |
Bottom line
| Fiscal year | LNTH | MYGN |
|---|---|---|
| FY2025 | $233.6M | $-365.9M |
| FY2024 | $312.4M | $-127.3M |
| FY2023 | $326.7M | $-263.3M |
| FY2022 | $28.1M | $-112.0M |
| FY2021 | $-71.3M | $-27.2M |
| FY2020 | $-13.5M | $-223.6M |
| FY2019 | $31.7M | $-199.5M |
| FY2018 | $40.5M | $4.6M |
| FY2017 | $123.4M | $133.3M |
| FY2016 | $26.8M | $17.4M |
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$717,109,000 | LNTH |
| FY2024 | +$696,310,000 | LNTH |
| FY2023 | +$543,229,000 | LNTH |
| FY2022 | +$256,661,000 | LNTH |
| FY2021 | −$265,392,000 | MYGN |
| FY2020 | −$217,690,000 | MYGN |
| FY2019 | −$291,263,000 | MYGN |
| FY2018 | −$507,726,000 | MYGN |
| FY2017 | −$412,322,000 | MYGN |
| FY2016 | −$426,847,000 | MYGN |
| FY2015 | −$447,039,000 | MYGN |
| FY2014 | −$420,900,000 | MYGN |
| FY2013 | −$494,528,000 | MYGN |
The higher-revenue side has changed between LNTH and MYGN over this period. The gap has widened since the earliest year compared.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +59.5 pp | LNTH |
| FY2024 | +35.6 pp | LNTH |
| FY2023 | +60.2 pp | LNTH |
| FY2022 | +19.5 pp | LNTH |
| FY2021 | −12.8 pp | MYGN |
| FY2020 | +36.2 pp | LNTH |
| FY2019 | +40.4 pp | LNTH |
| FY2018 | +11.3 pp | LNTH |
| FY2017 | +19.3 pp | LNTH |
The higher net margin has changed hands between LNTH and MYGN over this period.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MYGN's net margin has been more volatile than LNTH's over the 9 comparable fiscal years — 19.7 percentage points of standard deviation against 15.1.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between LNTH and MYGN over these 9 fiscal years — LNTH led in 8 and MYGN in 1.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LNTH's return on equity has been more volatile than MYGN's over the 8 comparable fiscal years — 30.3 percentage points of standard deviation against 20.2.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between LNTH and MYGN over these 8 fiscal years — LNTH led in 7 and MYGN in 1.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.